Anti-inflammatory complexes

A complex comprising a compound of formula II:

• wherein each of G1, G2, G3, and G4 is N or CRD;
• Z is S, O, Se, SO, SO2, or NH;
• R1 is —C(O)X, wherein X is independently a protecting group, a halogen, R, —OR, —SR, —N(R)2, a substituted or unsubstituted hydrazine, a substituted or unsubstituted 6-10 membered aryl ring, a substituted or unsubstituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• —NO2;
• —PO3H;
• —SO3H;
• —CN;
• substituted or unsubstituted heteroaryl:
• or one of the following moieties:
• wherein each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, C1-6 heteroaliphatic, aryl, heteroaryl, or a cyclic radical;
• R2 is an optionally substituted aliphatic group;
• RA, RB, RC, and RD are independently H, —NO2, —OR10, halogen, alkylN(R10)2, —N(R10)2, —C(═O)R10, —C(═O)OR10, —S(R10), azido, —S—C≡N, alkyl, aryl, alkenyl, alkynyl, or a cyclic radical, wherein RA, RB, RC, and RD are further optionally substituted;
• R10 is H, alkyl, aryl, alkenyl, alkynyl, or a cyclic radical, wherein R10 is further optionally substituted;
• and
• a binding partner non-covalently associated with the compound of formula II, and the amount of the binding partner is present in a ratio within the range of about 0.5:4.5 to 2:1 relative to the compound of formula II.

A complex comprising a compound of formula III:

• wherein:
• L2 is a bivalent, branched or unbranched, saturated or unsaturated, C2-C6 hydrocarbon chain wherein one or more methylene units of L is independently replaced by —O—, —S—, —N—, —C(O)—, —CF2—, —C(═CH2)—, —CH═CH—, or an optionally substituted arylene, heteroarylene, C3-C6 cycloalkylene, C3-C6 heterocycloalkylene, or an 8-10-membered bicyclic heterocyclic moiety,
• and wherein L2 is optionally substituted by one or more groups selected from halogen, C1-C6 alkyl, phenyl, biphenyl, -benzyl, —CH2-phenol, —CH(phenyl)2, —OH, —NH2, —NHC(O)CH3, —NHC(O)NHCH2CH3, —C(O)NH2, —C(O)NHCH2CH3, —CH2C(O)OCH2phenyl, —(CH2)2SCH3, —(CH2)2C(O)NH2, —(CH2)2C(O)OH, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5- to 7-membered monocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 7-10 membered bicyclic heterocyclyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• M is —C(O)—, —C(S), or —SO2—;
• R11 is hydrogen, F, CF3, C1-C4 alkyl, —OH, —C(O)CH3, —NH(OR12), —N(R12)2, —NHN(R12)2, —SO2R12, —NH-phenyl, —SO2-phenyl, -phenyl-NO2, or —OR12, wherein each R12 is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic or C1-6 heteroaliphatic;
• R1 is —C(O)X, wherein X is independently R12, —C(O)NHNH2, —OR12, a hydrogen, aryloxy, amino, alkylamino, dialkylamino, heteroaryloxy, hydrazine, a 6-10 membered aryl ring, a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• and
• R2 is a substituted or unsubstituted, branched or unbranched C10-C25 aliphatic moiety;
• Z is —O—, —N—, —S—, —Se—, —S(O)—, —S(═N)—, —SO2—, —Se(O)—, or —Se(O)2—;
• and
• a binding partner non-covalently associated with the compound of formula III, and the amount of the binding partner is present in a ratio within the range of about 0.5:4.5 to 2:1 relative to the compound of formula III.

A complex comprising a compound of formula IV:

• wherein:
• R14 is an optionally substituted heteroaryl group or:
• R13 is an aliphatic group substituted with one or more R19 groups;
• R15 is an optionally substituted heteroaryl group, or a group selected from:
• Y is selected from H, —NH2, —OH, —NH-phenyl, —NHC(O)CH3, —NHCH3, or —(C1-C8)alkyl;
• W is independently —C(R22)— or N;
• R22 is halo, hydrogen, CF3, N(R17)2, oxo, alkyl, alkenyl, alkynyl or aryl;
• J is —O—, S, —N—, —N(R17)—, —C(R23)— or —C(R18)—;
• A is independently —C(R23)—, —N— or —O—;
• R23 is hydrogen, F, CH3, CF3, OH, —NH2, —NHNH2, alkyl, alkenyl, alkynyl or aryl;
• R16 is H, alkyl, aryl, alkenyl, alkynyl, or a cyclic radical, wherein R16 is optionally substituted with one or two R19 groups;
• R17 is independently H, alkyl, aryl, alkenyl, or alkynyl, or —C(═O)O-butyl wherein R17 is optionally substituted with one or two R19 groups;
• R18 is H, alkyl, aryl, alkenyl, alkynyl, or a cyclic radical, wherein R18 is optionally substituted with one or two R19 groups;
• R19 is —NHC(═O)(C1-C8)alkyl, —(C1-C8)alkyl, —(C1-C8)alkenyl, —(C1-C8)alkynl, phenyl, —(C2-C5)heteroaryl, —(C1-C6)heterocycloalkyl, —(C3-C7)cycloalkyl, —O—(C1-C8)alkyl, —O—(C1-C8)alkenyl, —O—(C1-C8)alkynyl, —O-phenyl, —CN, —OH, oxo, halo, —C(═O)OH, 'COhalo, —OC(═O)halo, —CF3, N3, NO2, —NH2, —NH((C1-C8)alkyl), —N((C1-C8)alkyl)2, —NH(phenyl), —N(phenyl)2, —C(═ONH2, —C(═O)NH((C1-C8)alkyl), —C(═O)N((C1-C8)alkyl)2, —C(═O)NH(phenyl), —C(═O)N(phenyl)2, —OC(═O)NH2, —NHOH, —NOH((C1-C8)alkyl), —NOH(phenyl), —OC(═O)NH((C1-C8)alkyl), —OC(═O)N((C1-C8)alkyl)2, —OC(═O)NH(phenyl), —OC(═O)N(phenyl)2, —CHO, —CO((C1-C8)alkyl), —CO(phenyl), —C(═O)O((C1-C8)alkyl), —C(═O)O(phenyl), —OC(═O)((C1-C8)alkyl), —OC(═O)(phenyl), —OC(═O)O((C1-C8)alkyl), —OC(═O)O(phenyl), —S—(C1-C8)alkyl, —S—(C1-C8)alkenyl, —S—(C1-C8)alkynyl, and —S-phenyl, —NHS(O)2-phenyl, —NHS(O)2-alkyl, —NHS(O)2—(C1-C8)alkenyl, —NHS(O)2—(C1-C8)alkynyl, —NHS(O)2, —SC(O)-phenyl, —SC(O)-alkyl, —SC(O)—(C1-C8)alkenyl, —SC(O)—(C1-C8)alkenyl, —SC(O)—(C1-C8 alkynyl), —O—(═O)2—(C1-C8)alkyl, —O—S(═O)2—(C1-C8)alkenyl, —O—S(═O)2—(C1-C8)alkynyl, —O—S(═O)2-phenyl, —(CH2)nNH2, —(CH2)n—NH((C1-C8)alkyl), —(CH2)nN((C1-C8)alkyl)2, —(CH2)nNH(phenyl), or —(CH2)nN(phenyl)2, wherein n is 1 to 8;
• R20 is H, alkyl, alkenyl, alkynyl, aryl, —N(R17)2;
• R21 is H, alkyl, alkenyl, alkynyl, aryl, —CN, —S(═O)2—R18 or —C(═O)O-t-butyl;
• and
• Q is —S—, —O—, —Se—, —S(O)—, —SO2—, or —NH—;
• each of the dashed lines independently represents the presence or absence of a double bond;
• and
• a binding partner non-covalently associated with the compound of formula IV, and the amount of the binding partner is present in a ratio within the range of about 0.5:4.5 to 2:1 relative to the compound of formula IV.

A complex comprising a compound of formula V:

• wherein:
• R14 is an optionally substituted heteroaryl group or:
• Y is selected from H, —NH2, —OH, —NH-phenyl, —NHC(O)CH3, —NHCH3, or —(C1-C8)alkyl;
• R13 is an aliphatic group substituted with one or more R19 groups;
• R24 is independently H,
• or —NH—S(O)2R25;
• R25 is independently H, (C1-C4)alkyl or aryl;
• R17 is independently H, alkyl, aryl, alkenyl, or alkynyl, wherein R17 is optionally substituted with one or two R19 groups;
• R18 is H, alkyl, aryl, alkenyl, alkynyl, or a cyclic radical, wherein R18 is optionally substituted with one or two R19 groups;
• R19 is —NHC(═O)(C1-C8)alkyl, —(C1-C8)alkyl, —(C1-C8)alkenyl, —(C1-C8)alkynyl, phenyl —(C2-C5)heteroaryl, —(C1-C6)heterocycloalkyl, —(C3-C7)cycloalkyl, —O—(C1-C8)alkyl, —O—(C1-C8)alkenyl, —O—(C1-C8)alkynyl, —O-phenyl, —CN, —OH, oxo, halo, —C(═O)OH, —COhalo, —OC(═O)halo, —CF3, N3, NO2, —NH2, —NH((C1-C8)alkyl), —N((C1-C8)alkyl)2, —NH(phenyl), —N(phenyl)2, —C(═O)NH2, —C(═O)NH((C1-C8)alkyl), —C(═O)N((C1-C1-C8)alkyl)2, —C(═O)NH(phenyl), —C(═O)N(phenyl)2, —OC(═O)NH2, —NHOH, —NOH((C1-C8)alkyl), —NOH(phenyl), —OC(═O)NH((C1-C8)alkyl), —OC(═O)N((C1-C8)alkyl)2, —OC(═O)NH(phenyl), —OC(═O)N(phenyl)2, —CHO, —CO((C1-C8)alkyl), —CO(phenyl), —C(═O)O((C1-C8)alkyl), —C(═O)O(phenyl), —OC(═O)((C1-C8)alkyl), —OC(═O)(phenyl), —OC(═O)O((C1-C8)alkyl), —OC(═O)O(phenyl), —S—(C1-C8)alkyl, —S—(C1-C8)alkenyl, —S—(C1-C8)alkynyl, and —S-phenyl, —NHS(O)2-phenyl, —NHS(O)2-alkyl, —NHS(O)2-(C1-C8)alkenyl, —NHS(O)2—(C1-C8)alkynyl, —NHS(O)2, —SC(O)-phenyl, —SC(O)-alkyl, —SC(O)—(C1-C8)alkenyl, —SC(O)—(C1-C8 alkynyl) —O—S(═O)2—(C1-C8)alkyl, —O—S(═O)2—(C1-C8)alkenyl, —O—S(═O)2—(C1-C8)alkynyl, —O—S(═O)2-phenyl, —(CH2)nNH2, —(CH2)n—NH((C1-C8)alkyl), —(CH2)nN((C1-C8)alkyl)2, —(CH2)nNH(phenyl), or —(CH2)nN(phenyl)2, wherein n is 1 to 8;
• and
• a binding partner non-covalently associated with the compound of formula V, and the amount of the binding partner is present in a ratio within the range of about 0.5:4.5 to 2:1 relative to the compound of formula V.